EPO-Fc Human
- 产品详情
- 实验流程
Species | Human |
---|---|
Purity | >98% by SDS-PAGE and HPLC analyses. |
Endotoxin Level | Less than 0.2EU/ug of rHuEPO-Fc a as determined by LAL method. |
Formulation | Lyophilized from a 0.2um filtered concentrated solution in PBS, pH 7.4. |
Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20℃. Further dilutions should be made in appropriate buffered solutions. |
Target Background | Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients. Erythropoietin/Fc Chimera is a long-acting version of EPO. |
---|
Research Areas
For Research Use Only. Not For Use In Diagnostic Procedures.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.